Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Altrenogest (also known as Allyltrenbolone; A35957; RU2267; DRC6246; R-2267; A-35957; RU-2267; Allyl trenbolone; REGU-MATE; Regumate) is a progestogen structurally related to veterinary steroid trenbolone. It is a synthetic trienic C21 steroidal progestomimetic, belonging to the 19-nor-testosterone series. It is an orally active (pro)gestagen. Like all steroids, altrenogest acts by its liposolubility by penetrating the target cells where it binds to specific receptors. In veterinary medicine, altrenogest is used in gilts and mares for zootechnical purposes (oestrus synchronization).
ln Vitro |
The progestogen altrenogest (Allyltrenbolone) shares structural similarities with the veterinary steroid trenbolone. The degree of donor-recipient synchronization needed for a successful embryo transfer appears to be extended when mares receiving embryos are treated with Altrenogest (Allyltrenbolone)[1]. When it comes to controlling estrous behavior and the duration between estrus and ovulation, the gel and oil forms of Altrenogest (Allyltrenbolone) work equally well. therapy with altrenogest (Allyltrenbolone) that is initiated later in the diestrus seems to increase the likelihood of ovulation during therapy. When ovulation and luteolysis occur during treatment, the luteal phase that follows is often prolonged because the CL does not regress[2].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Parry-Weeks, L.C. and D.W. Holtan, Effect of altrenogest on pregnancy maintenance in unsynchronized equine embryo recipients. J Reprod Fertil Suppl, 1987. 35: p. 433-8.
[2]. Daels, P.F., et al., Persistence of the luteal phase following ovulation during altrenogest treatment in mares. Theriogenology, 1996. 46(5): p. 799-811. |
Molecular Formula |
C21H26O2
|
|
---|---|---|
Molecular Weight |
310.43
|
|
CAS # |
850-52-2
|
|
Related CAS # |
Altrenogest-d5
|
|
SMILES |
O([H])[C@@]1(C([H])([H])C([H])=C([H])[H])C([H])([H])C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])C([H])([H])C4=C([H])C(C([H])([H])C([H])([H])C4=C3C([H])=C([H])[C@@]21C([H])([H])[H])=O
|
|
InChi Key |
VWAUPFMBXBWEQY-ANULTFPQSA-N
|
|
InChi Code |
InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1
|
|
Chemical Name |
(8S,13S,14S,17R)-17-allyl-17-hydroxy-13-methyl-1,2,6,7,8,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2213 mL | 16.1067 mL | 32.2134 mL | |
5 mM | 0.6443 mL | 3.2213 mL | 6.4427 mL | |
10 mM | 0.3221 mL | 1.6107 mL | 3.2213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.